Lineage Cell Therapeutics Inc (AMEX:LCTX) price on Thursday, February 27, fall -8.32% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.57.
A look at the stock’s price movement, the close in the last trading session was $0.63. Turning to its 52-week performance, $1.61 and $0.48 were the 52-week high and 52-week low respectively. Overall, LCTX moved -8.81% over the past month.
Lineage Cell Therapeutics Inc’s market cap currently stands at around $126.61 million, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 1.62M for the company’s revenue for the quarter, with a low and high estimate of 840k and 3.78M respectively. The average forecast suggests down to a -23.46% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 8.25M, representing a -7.73% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that LCTX is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
LCTX’s current price about -13.64% and -4.48% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 39.12, while 7-day volatility ratio is 8.29% and 8.73% in the 30-day chart. Further, Lineage Cell Therapeutics Inc (LCTX) has a beta value of 1.26, and an average true range (ATR) of 0.05.
If we refocus on Lineage Cell Therapeutics Inc (AMEX:LCTX), historical trading data shows that trading volumes averaged 2.04 million over the past 3 months. The company’s latest data on shares outstanding shows there are 220.42 million shares.
The 0.44% of Lineage Cell Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 52.93% of the company’s shares. Current price change has pushed the stock 14.31% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the LCTX stock continues to rise going into the next quarter.
